Cellectis to Report Second Quarter 2025 Financial Results on August 4, 2025

New York, NY - July 28, 2025 - Cellectis (the "Company") (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the second quarter 2025 ending June 30, 2025 on Monday August 4, 2025 after the close of the US market.

The publication will be followed by an investor conference call and webcast on Tuesday August 5, 2025 at 8:00 AM ET / 2:00 PM CET. The call will include the Company's second quarter results and an update on business activities.

Details for the call are as follows:

Dial in information:

Domestic: +1-800-343-5172

International: +1-203-518-9856

Conference ID: CLLSQ2

Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1727030&tp_key=10a62ee950